Загрузка видео...
Не удалось загрузить видео
Learn more about Signatera and the foundational technology that is transforming care for patients with cancer. Hear directly from Natera CEO Steve Chapman on how Signatera can detect molecular residual disease and help determine whether therapy is working. #CancerCare #Signatera #MRD #Oncology #Natera
84,651 просмотров • 1 год назад •via X (Twitter)
Комментарии: 1

Randy Holcombe1 год назад
@SteveChapmanCEO In a case of post op colo-rectal cancer, what does it mean when CEA starts going up but Signatera is negative?







